eleven biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. eleven biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the company’s unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders.
Company profile
Ticker
CARM
Exchange
Website
CEO
Thomas Cannell
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Eleven Biotherapeutics, Inc., Sesen Bio, Inc.
SEC CIK
Corporate docs
Subsidiaries
CTx Operations, Inc. ...
CARM stock data
Latest filings (excl ownership)
8-K
Other Events
10 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
9 Nov 23
8-K
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
1 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
10 Aug 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
EFFECT
Notice of effectiveness
16 May 23
Transcripts
CARM
Earnings call transcript
2021 Q1
10 May 21
CARM
Earnings call transcript
2020 Q3
9 Nov 20
CARM
Earnings call transcript
2020 Q3
9 Nov 20
CARM
Earnings call transcript
2020 Q1
11 May 20
CARM
Earnings call transcript
2019 Q4
16 Mar 20
CARM
Earnings call transcript
2019 Q3
12 Nov 19
CARM
Earnings call transcript
2019 Q1
13 May 19
CARM
Earnings call transcript
2018 Q4
4 Mar 19
CARM
Earnings call transcript
2017 Q3
14 Nov 17
Latest ownership filings
4
John Hohneker
1 Apr 24
3
John Hohneker
1 Apr 24
SC 13G
AbbVie Biotechnology Ltd
13 Mar 24
SC 13D/A
HealthCap VII, L.P.
7 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Richard Steven Morris
2 Feb 24
4
Michael Klichinsky
2 Feb 24
4
Steven Kelly
2 Feb 24
SC 13G/A
Longview Innovation Corp.
2 Feb 24
SC 13D/A
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.16 mm | 83.16 mm | 83.16 mm | 83.16 mm | 83.16 mm | 83.16 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.45 mm | 4.28 mm | 7.00 mm | 4.35 mm |
Cash used (since last report) | n/a | n/a | 50.99 mm | 29.30 mm | 47.92 mm | 29.77 mm |
Cash remaining | n/a | n/a | 32.17 mm | 53.86 mm | 35.24 mm | 53.40 mm |
Runway (months of cash) | n/a | n/a | 4.3 | 12.6 | 5.0 | 12.3 |
Institutional ownership, Q3 2023
37.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 9 |
Closed positions | 3 |
Increased positions | 14 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 30.50 bn |
Total shares | 15.66 mm |
Total puts | 27.80 k |
Total calls | 499.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
HealthCap VII | 3.40 mm | $0.00 |
Longview Innovation | 2.90 mm | $36.41 mm |
Trustees Of The University Of Pennsylvania | 1.76 mm | $7.44 mm |
BLK Blackrock | 1.75 mm | $7.42 bn |
TPG GP A | 1.68 mm | $7.12 bn |
Vanguard | 1.56 mm | $6.60 bn |
Geode Capital Management | 503.79 k | $2.13 bn |
STT State Street | 482.12 k | $2.04 bn |
Renaissance Technologies | 204.70 k | $866.00 k |
Bridgeway Capital Management | 203.81 k | $862.12 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | John Hohneker | Stock Option Common Stock | Grant | Acquire A | No | No | 2.09 | 38,700 | 80.88 k | 38,700 |
31 Jan 24 | Richard Steven Morris | Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 170,500 | 358.05 k | 170,500 |
31 Jan 24 | Michael Klichinsky | Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 170,500 | 358.05 k | 170,500 |
31 Jan 24 | Steven Kelly | Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 438,000 | 919.80 k | 438,000 |
News
Carisma Therapeutics To Present New Data At ASGCT Annual Meeting
22 Apr 24
BTIG Initiates Coverage On CARISMA Therapeutics with Buy Rating, Announces Price Target of $6
11 Apr 24
HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9
2 Apr 24
CARISMA Therapeutics Q4 EPS $(0.52) Beats $(0.55) Estimate, Sales $4.29M Beat $2.90M Estimate
1 Apr 24
Press releases
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
24 Apr 24
Carisma Therapeutics to Present at Upcoming Conferences
3 Apr 24
Carisma Therapeutics Announces Changes to its Board of Directors
1 Apr 24
Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
21 Mar 24
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
28 Feb 24